GHRS

GH Research PLC
CAPPED RATING

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GH Research PLC (GHRS) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D-
Factor Score 1.1 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -10.4
EV / EBITDA -13.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -31.7%
Price Return 12M 42.2%
Catalyst Signal 0.00
Market Cap $1.3B
TTM Revenue N/A
Price / Sales N/A
ROE -18.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D- (1.1) C- (2.1) C (2.3) C+ (2.6) C- (2.1)
2026-11-05 C+ (2.5) D- (1.1) C- (2.0) C (2.4) C+ (2.7) C- (2.1)
2026-10-29 C+ (2.5) D- (1.1) C- (2.0) B- (3.0) C+ (2.7) C (2.2)
2026-10-22 C+ (2.5) D- (1.1) C- (2.0) B- (3.1) C+ (2.6) C (2.3)
2026-10-15 C+ (2.5) D- (1.1) C- (2.0) B (3.2) C+ (2.6) C (2.3)
Page 1 of 4